Finanzen von Galmed Pharmaceuticals Ltd (GLMD)GLMDGalmed Pharmaceuticals Ltd

Evaluating the bottom line, Galmed Pharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.12%, provide a clear picture of how effectively GLMD converts its operational activities into shareholder value.

In the context of the broader market, GLMD competes directly with industry leaders such as ONCO and JUNS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, GLMD's gross margin of N/A stands against ONCO's 25.13% and JUNS's 86.88%. Such benchmarking helps identify whether Galmed Pharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

Galmed Pharmaceuticals has shown significant financial struggles, with a net income of -4,818,000 USD in Q4 2025 and a negative EPS of -2.86 reported in the last earnings. The company has consistently reported negative earnings over the past quarters, indicating ongoing financial distress.